New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:40 EDTAMGN, BAYRYEMA backs expanded indication for Nexavar for thyroid cancer
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Nexavar. Nexavar is currently indicated for the treatment of patients with hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. The CHMP has now recommended an extension to the indication to include the treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine. Nexavar is marketed by Bayer (BAYRY) and Amgen's (AMGN) Onyx Pharmaceuticals.
News For AMGN;BAYRY From The Last 14 Days
Check below for free stories on AMGN;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
06:16 EDTAMGNOptions expected to be active: TWTR BWLD AXP DWA PNRA AMGN X FB
Subscribe for More Information
06:00 EDTAMGNAmgen price target raised to $150 from $143 at Piper Jaffray
Subscribe for More Information
05:57 EDTBAYRYBayer reports Q2 net income EU 953M vs. EU 841M last year
Subscribe for More Information
05:55 EDTBAYRYBayer says Stivargahas approved in Europe for GIST
Subscribe for More Information
July 29, 2014
18:35 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTAMGNAmgen says total product sales increased 8% in Q2
Total product sales increased 8% for the second quarter of 2014 versus the second quarter of 2013. The increase was mainly driven by ENBREL, Kyprolis, Prolia and XGEVA. Product sales in the second quarter of 2013 included a positive adjustment of $185M to previous estimates for managed Medicaid rebates based on claims experience.
16:21 EDTAMGNAmgen to reduce global workforce by 12%-15%
The company announced a restructuring plan today to invest in continuing innovation and the launch of its new pipeline molecules, while improving its cost structure. Initial efforts include streamlining the organization, reducing layers of management, increasing managerial spans of responsibility and beginning implementation of a revised geographic site plan. As a first step, the company will reduce staff by 2,400-2,900, beginning later this year and continuing through 2015, predominantly in the U.S. This represents approximately 12% to 15% of Amgen’s global workforce. The company will also close its facilities in the states of Washington and Colorado
16:19 EDTAMGNAmgen raises FY14 EPS view to $8.20-$8.40 from $7.90-$8.20, consensus $8.09
Subscribe for More Information
16:16 EDTAMGNAmgen reports Q2 EPS $2.37, consensus $2.07
Reports Q2 revenue $5.18B, consensus $4.9B.
15:53 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:49 EDTAMGNEarnings Preview: Amgen counting on newer drugs to boost sales
Subscribe for More Information
11:11 EDTAMGNAmgen technical comments before results
Subscribe for More Information
July 25, 2014
09:19 EDTAMGNAmgen weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:36 EDTAMGNEMA adopts positive opinion on new indication for Xgeva
Subscribe for More Information
07:32 EDTBAYRYAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
05:35 EDTAMGN, BAYRYBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 24, 2014
13:06 EDTBAYRYBayer treatment for systemic sclerosis receives FDA orphan designation
Subscribe for More Information
07:12 EDTBAYRYEvogene announces amendment to Bayer wheat agreement
Subscribe for More Information
July 21, 2014
07:14 EDTBAYRYAmerican Association of Physicists in Medicine to hold annual meeting
56th Annual Meeting of AAPM to be held in Austin, Texas on July 20-25.
July 17, 2014
16:10 EDTAMGNAmgen announces positive Phase 3 results for AMG 416
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use